Cellular Biology
Science NewsView All Science News
11/10/2018 | The 2018 guideline addresses the practical management of patients with high blood cholesterol and related disorders.
11/10/2018 | Science News coverage of selected presentations and interviews from AHA's Scientific Sessions 2018. Nov. 10-12, 2018 in Chicago, Ill.
08/22/2018 | CIRCULATION RESEARCH Featured articles for August 2018
BCVS 2019 Scientific Sessions
Basic Cardiovascular Sciences 2019 Scientific Sessions
July 29–Aug. 1, 2019
Boston, Massachusetts
Related Councils
Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB)
The Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) contributes to the mission and objectives of the American Heart Association (AHA) through efforts in the fields of arteriosclerosis, thrombosis and vascular biology. The council advances and coordinates research, addresses prevention, improves methods for diagnosis and treatment, and works actively with other organizations concerned with these issues. The council disseminates reliable information related to these fields through its annual conference, many awards and lectures, and the AHA's journal, Arteriosclerosis, Thrombosis, and Vascular Biology.
Mary Sorci-Thomas, PhD, FAHA
Chair, Council on Arteriosclerosis, Thrombosis and Vascular Biology
Council on Basic Cardiovascular Sciences (BCVS)
The American Heart Association (AHA) created the Council on Basic Cardiovascular Sciences (BCVS) in 1999 to promote research and education. Our goal is to improve understanding of mechanisms of basic cardiovascular regulation to support the development of new therapies and insights into clinical cardiovascular disease. Special emphasis is placed on integrating molecular/cellular and physiological approaches to address problems relating to functional genomics, cell signaling, myocardial biology, circulatory physiology, pathophysiology and peripheral vascular disease.
Joseph C. Wu, MD, PhD, FAHA
Chair, Council on Basic Cardiovascular Sciences
Council on Genomic and Precision Medicine (GPM)
The mission of the American Heart Association Council on Genomic and Precision Medicine (GPM) is to advance the discovery and translation of biological insights gained from genetics and omics technologies to improve cardiovascular and brain health. Our constituency’s expertise spans across genetics, genomics, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, population health, clinical genetics and genomic medicine, with the ultimate goal of more precise risk prediction, treatment and prevention for patients and the population. Integral to the American Heart Association’s goals, the GPM Council provides a premier inter-disciplinary forum promoting and integrating new knowledge from molecules to populations in translational cardiovascular science and precision medicine.
Thomas J. Wang, MD, FAHA
Chair, Council on Genomic and Precision Medicine
Since 1949, the American Heart Association has spent more than $4 billion on scientific research (opens in a new window) to increase our knowledge about cardiovascular diseases and stroke. Our research programs have contributed to many important scientific advances, which touch every community.